Overview

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Status:
Completed
Trial end date:
2007-11-08
Target enrollment:
Participant gender:
Summary
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction. The study will assess incidence and tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on expression of markers of inflammation.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Aspirin
Vorapaxar